Effector cell Baseline state Fc Receptor No effector cell engagement Antibod小y No complement activation No signalling Antigen larget cell ③ ④ Macrophage or Phagocytic NK cell Macrophage cell effector effector 1.Fix complement:initiate 2.Crosslink FcRlll.Initiate 3.Crosslink FcyRll 4.Crosslink antigens on opsoniztion,lysis, ADCC and cytokine release. Inhibit effector cell. cancer cell.Initiate signals, inflammation. block growth or survival. Protection from tumor Protection from tumor No protection from tumor Protection from tumor
Adapted from Houghton AN, et al. Nature Med 2000;6:373
VEGF Over-expression in Selected Tumours Tumour Type Tumors Correlation NSCLC 45-55% Recurrence,Survival Colorectal 40-60% Recurrence,Survival Breast 30-60% Vascular density, RFS, Survival Prostate 30% Vascular density, RFS Renal Cell 30-100% Vascular density
VEGF Over-expression in Selected Tumours Tumour Type % Tumors Correlation NSCLC 45 - 55% Recurrence, Survival Colorectal 40 - 60% Recurrence, Survival Breast 30 - 60% Vascular density, RFS, Survival Prostate 30% Vascular density, RFS Renal Cell 30 - 100% Vascular density
The Price of Success: Bevacizumab (Avestin) 80 kg patient;5mg/kg dose(!!!);20 doses 。$2,140-$2,750per400-ng vial >$42,800-$55,00U.S./patient
The Price of Success: Bevacizumab (Avestin) • 80 kg patient; 5mg/kg dose(!!!); 20 doses • $2,140 - $2,750 per 400-mg vial ¾ $42,800 - $55,00 U.S./patient